id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-303017-4zx94rm6	Barbieri, Antonio	Can Beta-2-Adrenergic Pathway Be a New Target to Combat SARS-CoV-2 Hyperinflammatory Syndrome?—Lessons Learned From Cancer	2020-09-30		.txt	text/plain	3539	191	41	This hypothesis relies on different pieces of evidence: IL-6, TNFa, and IL-1b promote Th17 response and are associated with inflammatory symptoms including fever, and the two latter are also associated with vascular permeability and leakage; IL-17 has a broad inflammatory effect and together with GM-CSF is involved in inflammatory and autoimmune disease; Covid-19 patients have a significantly increased number of CCR6+ Th17 cells (4) ; elevated TH17 and IL-17 related pathways are increased in SARS-CoV, MERS-CoV, and H1N1 influenza virus patients (14) (15) (16) ; In MERS-CoV patients, IL-17 and low IFNg are associated with worse prognosis (14) . Targeting beta-2adrenergic pathway was shown to reduce inflammatory cytokine and Th17 response in different settings such as cancer and autoimmune diseases. Two different reports on cancer patients show that propranolol treatment reduces inflammatory cytokines including IL-6 and TNFa, inflammation-related transcription factors such as NFkB and STAT3 and reduces the activation of Treg lymphocytes (36, 37) .	./cache/cord-303017-4zx94rm6.txt	./txt/cord-303017-4zx94rm6.txt